Zoledronic Acid CAS 118072-93-8 Dị Ọcha ≥99.7% API Ogo dị elu
Nye ya na ịdị ọcha dị elu yana ịdị mma kwụsie ike
Aha Kemịkal: Zoledronic Acid
Ọkụ: 118072-93-8
Farnesyl Diphosphate (FPP) Synthase Inhibitor nke nwere ike
API Ogo dị elu, mmepụta azụmahịa
| Aha Chemical | Zoledronic acid |
| Ụdị okwu | ZOL 446, ZA, Zoledronate, CGP-4244, GP42446A, Zometa, Zomera;[1-Hydroxy-2- (1H-imidazol-1-yl) -ethylidene] bisphosphonic acid. |
| Nọmba CAS | 118072-93-8 |
| Nọmba CAT | RF-API90 |
| Ọnọdụ Ahịa | Na Akụrụngwa, Mpụta Ihe ruru narị narị kilograms |
| Usoro ihe omimi | C5H10N2O7P2 |
| Ibu molekụla | 272.09 |
| Ebe Na-agbaze | 193.0-204.0 ℃ |
| Ụdị | Ruifu Chemical |
| Ihe | Nkọwapụta |
| Ọdịdị | Ntụ ntụ kristal na-acha ọcha ruo na-agbanyụọ |
| njirimara | IR Spectrum nke sample dabara na nke ọkọlọtọ ntụaka |
| pH | 2.0-4.0 |
| Solubility | Na-agbaze nke ọma na 0.1N Sodium Hydroxide Solution, Na-agbaze ntakịrị n'ime mmiri yana 0.1N Hydrochloric Acid, Na-adịghị Apụ Apụ na Ethanol |
| Ihe ndị emetụtara | |
| Ọdịghị ọcha nke Onye ọ bụla | ≤0.10% |
| Mgbakọta adịghị ọcha | ≤0.30% |
| Ọnwụ na ihicha | 5.0% ~ 7.0% |
| Chloride | ≤0.02% |
| Phosphite | ≤0.50% |
| Phosphate | ≤0.50% |
| Ọla dị arọ | ≤10ppm |
| Ịdị ọcha | ≥99.7% |
| Nlele ọkọlọtọ | Standardkpụrụ ụlọ ọrụ |
| Ojiji | API, FPP Synthase Inhibitor, Hypercalcemia nke Malignancy (HCM) |
ngwugwu: Kalama, Aluminom foil bag, kaadiboodu drum, 25kg / Drum, ma ọ bụ dị ka ndị ahịa chọrọ.
Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ọkụ, mmiri mmiri na ụmụ ahụhụ.
Zoledronic acid (CAS 118072-93-8) bụ ihe na-egbochi bisphophonate farnesyl diphosphate (FPP) synthase inhibitor (IC50=20 nM).Na-egbochi mkpụkọ ọkpụkpụ na-agbapụta osteoclast.Na-egbochikwa nrịbama Ras na uto tumor, ma na-ebute apoptosis na mkpụrụ ndụ kansa pancreatic.Weghachite mgbanwe epithelial-mesenchymal ma gbochie mmeghari mkpụrụ ndụ kansa ara site na inactivation nke NF-κB.Ndị US FDA kwadoro Zoledronic acid na 2001 maka ọgwụgwọ hypercalcemia nke malignancy, mgbagha metabolic nke nwere ike ịdị egwu ndụ.Hypercalcemia nke malignancy nwere ike ime n'ihe ruru 50% nke ndị ọrịa a chọpụtara na ha nwere ọrịa kansa ara dị elu, otutu myeloma, na ọrịa cancer akpa ume na-abụghị obere cell.Ọnọdụ a na-ebilite mgbe ụdị kemịkalụ nke etuto ahụ na-emepụta na-ebute oke osteoclasts.Mgbe enwere mmụba nke mmebi ọkpụkpụ, a na-enwe ntọhapụ nke calcium n'otu oge na plasma.Mgbe mkpokọta calcium nke serum na-ebuli ngwa ngwa, akụrụ enweghị ike ijikwa ibu ahụ, yana hypercalcemia na-ebute.Zoledronic acid na-ebelata mkpokọta calcium plasma nke ọma site na mgbochi nke resorption ọkpụkpụ (mgbochi nke ọrụ osteoclastic na ntinye nke osteoclast apoptosis).Ọzọkwa zoledronic acid ka US FDA akwadoro maka ọgwụgwọ nke otutu myeloma na ọkpụkpụ metastases jikọtara ya na ọrịa kansa siri ike dabere (dịka ọmụmaatụ, ịkpọ isiala na ngụgụ).
